Skip to Main Content

A drug from Mirati Therapeutics designed to block the cancer protein called KRAS shrank tumors in 22% of patients with advanced colon cancer, according to results from a clinical trial presented Sunday.

When the Mirati drug, a pill called adagrasib, was combined with another targeted medicine, the colon cancer response increased to 43%.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment